Literature DB >> 1862162

Thyrotropin and prolactin responses to ECT in schizophrenia and depression.

Y Papakostas1, M Markianos, G Papadimitriou, L Lykouras, C Stefanis.   

Abstract

Thyroid stimulating hormone (TSH) and prolactin (PRL) plasma levels were studied during electroconvulsive therapy (ECT) in five schizophrenic patients in a simulated ECT (SECT) controlled experimental design. The data were compared to those obtained from a group of 10 depressed patients treated with ECT. In the schizophrenic group, both PRL and TSH increased significantly during ECT compared to SECT, as they did in the depressive group during ECT. Thus, the hormonal TSH and PRL profile during ECT is similar in schizophrenia and depression. It is concluded that the changes in TSH and PRL induced by ECT are specifically linked to the current or the seizure, and are not related to the type of psychopathology.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1862162     DOI: 10.1016/0165-1781(91)90101-t

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

1.  Electroconvulsive shock does not modify striatal contents of dopamine in MPTP-treated mice.

Authors:  E Garcia; J Sotelo
Journal:  Neurochem Res       Date:  1993-05       Impact factor: 3.996

Review 2.  Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.

Authors:  Milagros Rojas; Daniela Ariza; Ángel Ortega; Manuel E Riaño-Garzón; Mervin Chávez-Castillo; José Luis Pérez; Lorena Cudris-Torres; María Judith Bautista; Oscar Medina-Ortiz; Joselyn Rojas-Quintero; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 3.  Systematic review of sex differences in the relationship between hormones and depression in HIV.

Authors:  Morgan C Turk; Caitlin J Bakker; Sade M Spencer; Sarah M Lofgren
Journal:  Psychoneuroendocrinology       Date:  2022-01-10       Impact factor: 4.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.